Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose antiretroviral therapy to reduce latent HIV-1 reservoir
2024-513366-18-00Phase 2Authorised
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lamivudine, maraviroc and dolutegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal. Primary endpoint: Latent cell reservoir size by measuring total and intact proviral DNA (IPDA). Planned start Apr 2025; status: authorised.
02
Drugs
lamivudinemaravirocdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-513366-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513366-18-00.